about
Chemical Variations on the p53 Reactivation ThemeFunctional characterisation of the WW minimal domain for delivering therapeutic proteins by adenovirus dodecahedronThe role of p53 in cancer drug resistance and targeted chemotherapyp53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening systemp53 is positively regulated by miR-542-3p.Contribution of p53 to metastasis.p53 is a key regulator for osthole-triggered cancer pathogenesis.Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.Targeting p53 by small molecules in hematological malignancies.Focused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space.RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.Recent progress in targeting cancer.Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer.Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action.p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.Updates on HIPK2: a resourceful oncosuppressor for clearing cancerSelective killing of p53-deficient cancer cells by SP600125.Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathwayUsing a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy.TP53 mutations in human cancer: database reassessment and prospects for the next decade.Radiobiological modifiers in clinical radiation oncology: current reality and future potential.Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line.ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylationEstrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides.Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.A novel facet of tumor suppression by p53: Induction of tumor immunogenicity.PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.Off and back-on again: a tumor suppressor's tale.Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening
P2860
Q26749008-309D9AD8-394E-4C3B-B8DE-4B5FB4017D36Q27318180-D034B7BA-655F-4F39-AD26-3BBB4D6994E4Q28072553-677A0DFA-5BB7-443E-A1A7-3743452827F0Q28478414-17D41D65-93EF-4A21-89D7-F01CECE2F5B8Q33758261-B9BE139E-6199-420F-8A8A-E787423FEBDAQ33776331-E193568D-386A-4008-9FB8-869CFC702350Q33821688-632A2904-4353-423E-AE65-0BC7E0C6A103Q34038417-BC30B407-B414-422D-A451-EAFCCCC7B541Q34636996-A59D4AB7-08BE-4933-8A02-332A3B45A8D5Q35158672-8E8A2CEA-9696-44F0-BB33-A9FFA709F2DEQ35187880-FAC8CC0D-D277-495B-B178-1CE390E366C4Q35740782-BD5F383B-B509-43F4-A2E1-7F86101477E6Q35842210-4006105E-4883-4A40-B931-5E55026DF05CQ35850522-6980B758-C84D-435C-A92A-291063A4F309Q36092864-09EE3A25-E2A1-4EA0-89A1-A3BDAEFC8307Q36204714-2849CD6F-399F-4833-97CA-3F68E17158C5Q36238666-8F668EDE-7746-483D-B641-7410647C86FAQ36733743-7B9CA787-DD25-4304-88C3-1D69B10192BBQ36782143-45AF407B-DB3E-45AA-962D-78CF1DEE551FQ37162374-9EE5FF7D-6000-45A5-9CD5-587F9E15F934Q37323049-58C9BD92-EC04-4D9A-B625-4ADA8D5894A8Q37631181-741DFF54-C8F0-434F-AF20-BE985EDD076FQ37874926-C1ECFB3F-CBF5-4138-9815-DA76D3C8701BQ38127721-C896226B-F0D2-4A3C-878C-3927FFFAFCD5Q38199075-6B4E2F88-1A56-4ACE-A7C6-3B5E7955DF9AQ38294597-18EB637C-6BB8-4E6C-AABB-B038D192F2F2Q38695489-B9651DE3-E37D-44EB-B701-3B38B0DACBC0Q38727892-45C5F9FF-4681-4276-A8BA-E1CC8BAA19A6Q38747225-0184FE27-3A06-44E5-9185-D8AA9F4A409AQ39506861-40D6005E-71C7-4252-88D8-3224C6A55984Q39621228-5B88B49C-213B-46C1-A41F-2C084A00A42FQ41453979-F3188DF1-265D-4823-84F4-63F6E2EF27C2Q42214198-43F6F611-90FF-4182-8011-11B2DF0729EFQ47274927-F4FCD277-600F-40A9-8AEB-BB1A84F144E8Q52558518-C50E2C7C-921D-47F0-91D3-7B8603F217F9Q52726519-555E6E65-AA24-43BA-950F-EEA5F1B9AA3EQ59125760-35300984-311A-452A-A3A1-AB315F407626
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Therapeutic targeting of p53 by small molecules.
@ast
Therapeutic targeting of p53 by small molecules.
@en
Therapeutic targeting of p53 by small molecules.
@nl
type
label
Therapeutic targeting of p53 by small molecules.
@ast
Therapeutic targeting of p53 by small molecules.
@en
Therapeutic targeting of p53 by small molecules.
@nl
prefLabel
Therapeutic targeting of p53 by small molecules.
@ast
Therapeutic targeting of p53 by small molecules.
@en
Therapeutic targeting of p53 by small molecules.
@nl
P1476
Therapeutic targeting of p53 by small molecules
@en
P2093
Galina Selivanova
P356
10.1016/J.SEMCANCER.2010.02.006
P577
2010-02-01T00:00:00Z